Research programme: T Cell Engagers therapeutics - Candid Therapeutics/EpimAb Biotherapeutics
Latest Information Update: 14 Jan 2025
Price :
$50 *
At a glance
- Originator Candid Therapeutics; EpimAb Biotherapeutics
- Class Antibodies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders